ArticleJapanese journal of ophthalmology2026
Outcomes of micropulse cyclophotocoagulation for refractory glaucoma in children.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate the outcomes of micropulse transscleral cyclophotocoagulation (MP-CPC) for refractory glaucoma in children. STUDY
designRetrospective study.
methodsWe evaluated the data from children with refractory glaucoma who underwent MP-CPC from July 2022 to December 2024 at the National Center for Child Health and Development and who were followed up for at least 3 months. The retrospective analysis included age; glaucoma type; history of glaucoma surgery; intraocular pressure (IOP) at baseline and at 1, 3, and 6 months postoperatively; medication score administered before and after surgery; visual acuity; and complications.
resultsTwenty-nine eyes of 24 patients (average age, 101.3 ± 68.1 months) were included in this study. The most common types of glaucoma were glaucoma associated with nonacquired ocular anomalies and glaucoma after cataract surgery, accounting for 11 eyes (37.9%). The average number of glaucoma surgeries performed before treatment was 1.9 ± 1.6. The average follow-up period was 16.1 ± 7.9 months. Using a mixed-effects model, the mean IOP decreased by -9.8 mm Hg at 1 month (P <.01), -7.5 mm Hg at 3 months (P <.01), and -7.4 mm Hg at 6 months (P <.01). The median medication score (interquartile range) decreased from 5 (4-6) preoperatively to 4 (3-5) at 1, 3, and 6 months postoperatively. After undergoing the first MP-CPC, 19 eyes (65.5%) required reoperation for glaucoma. Eleven eyes (37.9%) required reoperation within 6 months postoperatively, and 17 eyes (58.6%) required reoperation within 1 year.
conclusionMP-CPC effectively reduces IOP in children with refractory glaucoma without causing visual impairment or serious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.